Blueprint Medicines Corp (NASDAQ:BPMC) has been assigned a consensus rating of “Buy” from the fourteen brokerages that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eleven have given a buy rating to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $84.20.

Several equities analysts have recently commented on BPMC shares. Canaccord Genuity restated a “buy” rating and set a $80.00 price target (up from $66.00) on shares of Blueprint Medicines in a report on Wednesday, November 1st. Cowen restated a “buy” rating on shares of Blueprint Medicines in a report on Tuesday, October 31st. Zacks Investment Research upgraded shares of Blueprint Medicines from a “hold” rating to a “buy” rating and set a $87.00 price target on the stock in a report on Monday, January 8th. Goldman Sachs Group boosted their price target on shares of Blueprint Medicines from $82.00 to $99.00 and gave the company a “buy” rating in a report on Monday, December 11th. Finally, Raymond James Financial set a $82.00 price target on shares of Blueprint Medicines and gave the company a “buy” rating in a report on Sunday, December 10th.

Shares of Blueprint Medicines (BPMC) opened at $75.73 on Tuesday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 11.28 and a current ratio of 11.28. Blueprint Medicines has a one year low of $32.43 and a one year high of $92.00. The stock has a market cap of $3,389.88, a price-to-earnings ratio of -22.21 and a beta of 1.16.

Blueprint Medicines (NASDAQ:BPMC) last announced its earnings results on Tuesday, October 31st. The biotechnology company reported ($0.96) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.90) by ($0.06). Blueprint Medicines had a negative net margin of 437.83% and a negative return on equity of 43.11%. The firm had revenue of $8.07 million for the quarter, compared to analyst estimates of $5.35 million. During the same period last year, the firm earned ($0.62) earnings per share. Blueprint Medicines’s revenue for the quarter was up 31.0% compared to the same quarter last year. equities research analysts anticipate that Blueprint Medicines will post -3.75 earnings per share for the current year.

In related news, insider Marion Dorsch sold 18,334 shares of the company’s stock in a transaction on Tuesday, November 21st. The shares were sold at an average price of $65.45, for a total value of $1,199,960.30. Following the completion of the sale, the insider now directly owns 18,334 shares in the company, valued at $1,199,960.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Daniel Lynch sold 5,000 shares of the company’s stock in a transaction on Wednesday, November 15th. The stock was sold at an average price of $63.38, for a total transaction of $316,900.00. The disclosure for this sale can be found here. Corporate insiders own 3.40% of the company’s stock.

A number of large investors have recently modified their holdings of the stock. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Blueprint Medicines by 57.3% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,866 shares of the biotechnology company’s stock worth $141,000 after purchasing an additional 680 shares in the last quarter. Great West Life Assurance Co. Can boosted its holdings in Blueprint Medicines by 53.6% in the third quarter. Great West Life Assurance Co. Can now owns 3,332 shares of the biotechnology company’s stock worth $228,000 after purchasing an additional 1,163 shares in the last quarter. Bank of New York Mellon Corp boosted its holdings in Blueprint Medicines by 0.8% in the third quarter. Bank of New York Mellon Corp now owns 176,029 shares of the biotechnology company’s stock worth $12,264,000 after purchasing an additional 1,326 shares in the last quarter. Rhumbline Advisers boosted its holdings in Blueprint Medicines by 3.0% in the third quarter. Rhumbline Advisers now owns 45,033 shares of the biotechnology company’s stock worth $3,137,000 after purchasing an additional 1,329 shares in the last quarter. Finally, Ameritas Investment Partners Inc. boosted its holdings in Blueprint Medicines by 68.9% in the second quarter. Ameritas Investment Partners Inc. now owns 3,410 shares of the biotechnology company’s stock worth $173,000 after purchasing an additional 1,391 shares in the last quarter. Hedge funds and other institutional investors own 83.45% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Blueprint Medicines Corp (BPMC) Receives Consensus Rating of “Buy” from Brokerages” was first reported by Watch List News and is the property of of Watch List News. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark law. The correct version of this piece can be read at https://www.watchlistnews.com/blueprint-medicines-corp-bpmc-receives-consensus-rating-of-buy-from-brokerages/1848330.html.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. It focuses on crafting drug candidates that provide clinical responses to patients without adequate treatment options. It has developed a small molecule drug pipeline in cancer and a genetic disease.

Analyst Recommendations for Blueprint Medicines (NASDAQ:BPMC)

Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.